Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Investing > ALTERNATIVES TO BIOLOGIC MEDICINES WILL SHAKE UP RHEUMATOID ARTHRITIS SUFFERERS’ TREATMENT REGIMES
    Investing

    ALTERNATIVES TO BIOLOGIC MEDICINES WILL SHAKE UP RHEUMATOID ARTHRITIS SUFFERERS’ TREATMENT REGIMES

    Published by Gbaf News

    Posted on April 25, 2017

    5 min read

    Last updated: January 21, 2026

    Allianz Trade celebrates winning the Global Banking & Finance Review award for Best Trade Credit Insurance Company Asia Pacific 2022, highlighting its excellence in credit insurance solutions.
    Award ceremony celebrating Allianz Trade as Best Trade Credit Insurance Company Asia Pacific - Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    NRAS LAUNCHES VIDEO TO HELP RAISE AWARENESS OF THE CHANGE

    The National Rheumatoid Arthritis Society (NRAS) is launching an informative video at the British Society of Rheumatology (BSR) conference to help RA sufferers understand upcoming potential changes to their medication.

    Biologic medicines for Rheumatoid Arthritis (RA) and other autoimmune conditions revolutionised treatment in the early 2000s. Many of these medicines are now coming out of patent, which will enable other pharmaceutical manufacturers to bring their own versions of the medicines to market – these are called Biosimilars. The medications will not be exactly the same but are extremely similar to the original drugs on offer.

    For many people currently being treated on biologic medicines this will mean a potential change in their treatment regimen. Therefore NRAS has put together an educational video to answer peoples’ queries and ensure everyone is aware of these new developments.

    Biologic and Biosimilar treatments are currently a very hot topic in the world of immunology and can cause some confusion when people come to change between the two. In the video, Ailsa Bosworth, NRAS Founder and CEO, interviews NRAS Chief Medical Advisor Professor, Peter Taylor, on the topic.

    Ailsa commented: “For approximately 20% of the 690,000 people living with RA in the UK, who have the severest form of the disease, biologic treatments have offered far better control of their disease. Therefore, whenever any change presents itself there are always lots of questions from our members.

    The video is aimed at anyone currently suffering from RA and will hopefully answer a large number of their queries and both help and educate them. Viewers will undoubtedly have different levels of knowledge, understanding and indeed personal experience of Biologics and Biosimilars ranging from zero knowledge to considerable. Our aim is to help them make a more informed transition.”

    There are four key areas that will be explored in the video – these are based on questions that people with RA have asked NRAS over the past year and have also come from the work that they have done with the Oxford Academic Health Science Network on this subject. These include:

    1. The impact on patients, particularly changing treatment programmes that switch patients who are on an originator product to a Biosimilar
    2. How Biosimilars sit within the regulatory process
    3. How will safety data be collected?
    4. How income saved from switching might be used to improve patient outcomes and services

    The Video will be launched next week and will be available to watch here: https://www.videum.com/video/switching-to-biosimilars-a-conversation-with-peter-taylor/

    For further information on NRAS and for further advice on the change, visit www.nras.org.uk

    NRAS LAUNCHES VIDEO TO HELP RAISE AWARENESS OF THE CHANGE

    The National Rheumatoid Arthritis Society (NRAS) is launching an informative video at the British Society of Rheumatology (BSR) conference to help RA sufferers understand upcoming potential changes to their medication.

    Biologic medicines for Rheumatoid Arthritis (RA) and other autoimmune conditions revolutionised treatment in the early 2000s. Many of these medicines are now coming out of patent, which will enable other pharmaceutical manufacturers to bring their own versions of the medicines to market – these are called Biosimilars. The medications will not be exactly the same but are extremely similar to the original drugs on offer.

    For many people currently being treated on biologic medicines this will mean a potential change in their treatment regimen. Therefore NRAS has put together an educational video to answer peoples’ queries and ensure everyone is aware of these new developments.

    Biologic and Biosimilar treatments are currently a very hot topic in the world of immunology and can cause some confusion when people come to change between the two. In the video, Ailsa Bosworth, NRAS Founder and CEO, interviews NRAS Chief Medical Advisor Professor, Peter Taylor, on the topic.

    Ailsa commented: “For approximately 20% of the 690,000 people living with RA in the UK, who have the severest form of the disease, biologic treatments have offered far better control of their disease. Therefore, whenever any change presents itself there are always lots of questions from our members.

    The video is aimed at anyone currently suffering from RA and will hopefully answer a large number of their queries and both help and educate them. Viewers will undoubtedly have different levels of knowledge, understanding and indeed personal experience of Biologics and Biosimilars ranging from zero knowledge to considerable. Our aim is to help them make a more informed transition.”

    There are four key areas that will be explored in the video – these are based on questions that people with RA have asked NRAS over the past year and have also come from the work that they have done with the Oxford Academic Health Science Network on this subject. These include:

    1. The impact on patients, particularly changing treatment programmes that switch patients who are on an originator product to a Biosimilar
    2. How Biosimilars sit within the regulatory process
    3. How will safety data be collected?
    4. How income saved from switching might be used to improve patient outcomes and services

    The Video will be launched next week and will be available to watch here: https://www.videum.com/video/switching-to-biosimilars-a-conversation-with-peter-taylor/

    For further information on NRAS and for further advice on the change, visit www.nras.org.uk

    More from Investing

    Explore more articles in the Investing category

    Image for Understanding the Factors Shaping Bitcoin’s Current Market Conditions
    Understanding the Factors Shaping Bitcoin’s Current Market Conditions
    Image for Understanding Investment Management Consulting Services in the U.S. Market
    Understanding Investment Management Consulting Services in the U.S. Market
    Image for The Role of DST Sponsors and Service Providers in Delaware Statutory Trusts
    The Role of DST Sponsors and Service Providers in Delaware Statutory Trusts
    Image for Understanding Self-Directed IRA Structures and Platform Models
    Understanding Self-Directed IRA Structures and Platform Models
    Image for 1031 Exchanges and Delaware Statutory Trusts: What Investors Need to Know
    1031 Exchanges and Delaware Statutory Trusts: What Investors Need to Know
    Image for Excellence in Innovation – Strategic Investment & Economic Transformation Egypt 2025
    Excellence in Innovation – Strategic Investment & Economic Transformation Egypt 2025
    Image for What Is the Average Pension Pot in the UK? (By Age)
    What Is the Average Pension Pot in the UK? (By Age)
    Image for From Money Printing to Market Surge: The Macro Forces Driving Crypto in 2026
    From Money Printing to Market Surge: The Macro Forces Driving Crypto in 2026
    Image for  Millennials Aren’t Ignoring Retirement. They’re Rebuilding It.
    Millennials Aren’t Ignoring Retirement. They’re Rebuilding It.
    Image for BridgeWise Launches FixedWise, the First AI Solution Bringing Granular Bond Intelligence to the European Market
    BridgeWise Launches FixedWise, the First AI Solution Bringing Granular Bond Intelligence to the European Market
    Image for Why Financial Advisors Are Rethinking Gold Allocations
    Why Financial Advisors Are Rethinking Gold Allocations
    Image for From Opaque to Investable: Yaniv Bertele's Blueprint for Transparent Alternatives
    From Opaque to Investable: Yaniv Bertele's Blueprint for Transparent Alternatives
    View All Investing Posts
    Previous Investing PostTHE TOP 6 UK INDUSTRIES FOR FOREIGN DIRECT INVESTMENT
    Next Investing PostWHAT INVESTORS SHOULD CONSIDER AHEAD OF THE UPCOMING FRENCH PRESIDENTIAL ELECTIONS